ArticleCurrent pharmaceutical biotechnology2026
Network Pharmacology Analysis and Experimental Verification of Weinaian Capsule for Treating Gastric Cancer.
Article in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASF1A: A versatile histone chaperone bridging chromatin dynamics, disease mechanisms and clinical potential (Review).Experimental and therapeutic medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTraditional Chinese medicine has been widely used to treat gastric cancer, but the effect of the Weinaian capsule on gastric cancer is still unclear.
objectiveThis study aimed to find the potential therapeutic targets and pharmacological mechanisms of Weinaian capsule in gastric cancer.
methodsWe employed the network pharmacological analysis to find the therapeutic targets. Firstly, we searched the bioactive components of Weinaian capsule in TCMSP and the Swiss database. We downloaded disease gastric cancer targets from the GeneCards database and used the Venn diagram to identify common targets for disease and drugs. Then, we performed GO and KEGG pathway enrichment analyses, used the Cytoscape software to screen core targets and components, and constructed a drug-disease-target network. In addition, visual molecular docking and molecular dynamics simulation of targets and components with strong affinity were performed. Finally, we verified the effect of the drug on cell proliferation and metastasis using CCK8, clonal formation, and wound healing assays, and investigated the molecular mechanism by qRT-PCR.
resultsA total of 33 bioactive components were procured; 128 common targets for gastric cancer and drugs were screened. The GO and KEGG pathway enrichment analyses showed the PI3K-AKT pathway to be at the top. The core target AKT1 and the core component isorhamnetin exhibited the strongest molecular binding force and good binding stability. Compared to the control group, Weinaian capsule group inhibited gastric cancer cell proliferation and migration by down-regulating the expressions of PI3K and AKT.
conclusionWeinaian capsule inhibited cell proliferation and metastasis by affecting the PI3K-AKT pathway in gastric cancer.
Indexed as
Identifiers
40325807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.